Acute Coronary SyndromeNCT04564365
The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction
An observational study of Acute Coronary Syndrome, run by Chongqing Medical University at 1 site in China.
Trial summary
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Acute Coronary Syndrome
- What is being tested?
- beta-blocker
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 30 Jun 2019to 25 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patient had normal left ventricular ejection fraction (LVEF≥50%) after acute myocardial infarction.
Who may be able to join
- The diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal
Who cannot join
- History of heart failure Died in hospital
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
The first affiliated Hospital of Chongqing Medical University
Chongqing, 400042
Dongying Zhang, +8613608398395, zdy.chris@qq.com
About this study
Official title: Influence of Beta-Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.
- Conditions
- Acute Coronary Syndrome
- Being tested
- beta-blocker
- Keywords
- left ventricular ejection fraction, acute myocardial infarction, beta-blocker
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
beta-blockerDrug
To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
| Study group | Role | What they receive |
|---|---|---|
| with beta-blocker | Not described Receives: Drug: beta-blocker | |
| without beta-blocker | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
mortality
all-cause mortality
Measured: the median time of 8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2020
- Study start30 Jun 2019
- Primary completion25 Nov 2021 (estimated)
- Study completion25 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chongqing Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dongying Zhang, Chongqing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04564365
- Sponsor's protocol ID
- 2020-09-22
- Status last verified
- Jun 2021
- First submitted
- 22 Sep 2020
- Last updated
- 11 Nov 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Luo S, Liu H, Wen X. Hemoglobin Glycation Index and Prognosis in Patients With Acute Myocardial Infarction Without Reduced Left Ventricular Ejection Fraction: A Multicenter Retrospective Cohort Study. J Diabetes. 2026 Jul;18(7):e70257. doi: 10.1111/1753-0407.70257.
PubMed 42478107
Study at a glance
From the registry record, last updated by the sponsor on 11 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Beta-Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction
- ClinicalTrials.gov ID
- NCT04564365
- Acronym / sponsor ID
- 2020-09-22
- Conditions
- Acute Coronary Syndrome
- Keywords
- left ventricular ejection fraction, acute myocardial infarction, beta-blocker
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Chongqing Medical UniversityUniversity, hospital or other
- Study start
- 30 Jun 2019 (actual)
- Primary completion
- 25 Nov 2021 (estimated)
- Study completion
- 25 Dec 2021 (estimated)
- First posted
- 25 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| with beta-blocker | – | Drug: beta-blocker |
| without beta-blocker | – | – |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patient had normal left ventricular ejection fraction (LVEF≥50%) after acute myocardial infarction.
Key inclusion criteria (1 listed)
- The diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal
Key exclusion criteria (1 listed)
- History of heart failure Died in hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| beta-blockerTo investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction | Drug | with beta-blocker |
Primary outcome
mortality
Time frame: the median time of 8 months
all-cause mortality
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Nov 2021.
- Derived from this study: PubMed 42478107Luo S, Liu H, Wen X. Hemoglobin Glycation Index and Prognosis in Patients With Acute Myocardial Infarction Without Reduced Left Ventricular Ejection Fraction: A Multicenter Retrospective Cohort Study. J Diabetes. 2026 Jul;18(7):e70257. doi: 10.1111/1753-0407.70257.
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The first affiliated Hospital of Chongqing Medical University
Chongqing, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by Chongqing Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mortality (time frame: the median time of 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04564365, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Nov 2021.